European health agency recommends approving Moderna’s combined flu, COVID vaccine

robot
Abstract generation in progress

The European Medicines Agency (EMA) has recommended market authorization for Moderna’s combined mRNA COVID-19 and flu vaccine, mCombriax, for individuals aged 50 and older. This marks a significant milestone as it would be the first combined respiratory viral vaccine approved and the first mRNA flu shot globally. While the recommendation is a step towards approval, the European Commission still needs to adopt a decision for EU-wide marketing authorization.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments